ArticleTranslational lung cancer research2025
Long-term follow-up results from the GLORY study: phase II study of gumarontinib in East Asian patients with
Article in Translational lung cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion.Targeted oncology · 2026Article
- Unraveling the intricacies of small cell lung cancer: FAK splicing variants as a new feature and therapeutic vulnerability of small cell lung cancer.MedScience · 2026Article
- Long-term comparative effectiveness of tepotinib versus standard of care for MET exon 14 skipping-mutated non-small cell lung cancer.Therapeutic advances in medical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
32 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Gumarontinib has previously shown activity in patients with non-small cell lung cancer (NSCLC) harboring Methods: The single-arm, multicenter, open-label, phase II of the GLORY study was conducted at 42 centers across China and Japan. Patients with locally advanced or metastatic Results: The phase II stage of GLORY study included 84 patients. As of the data cutoff date on October 28, 2023, the ORR assessed by BIRC was 65.8% [95% confidence interval (CI): 54.3% to 76.1%], with 70.5% (95% CI: 54.8% to 83.2%) in treatment-naïve and 60.0% (95% CI: 42.1% to 76.1%) in pre-treated populations. The median duration of response (DOR) assessed by BIRC was 8.3 (95% CI: 6.2 to 18.3) months, the median progression-free survival (PFS) was 7.7 (95% CI: 7.6 to 9.7) months, and the median overall survival (OS) was 19.4 (95% CI: 12.1 to 30.1) months, with a median OS of 25.4 [95% CI: 11.7 to not evaluable (NE)] months in treatment-naïve population and 16.3 (95% CI: 8.7 to NE) months in the pre-treated population. The most common treatment-related adverse events (any grade) were oedema (67/84, 79.8%) and hypoalbuminemia (32/84, 38.1%). Grade ≥3 treatment-related adverse events occurred in 53.6% (45/84) patients. Treatment-related adverse events leading to permanent discontinuation occurred in 8.3% (7/84) of patients. Conclusions: Gumarontinib showed promising efficacy and acceptable toxicities in East Asian population, with a rapid onset of action, substantial and durable response, which can be converted into a long-term survival benefit.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.